Furthermore, antiestrogen therapy is the primary treatment for estrogen receptor (ER)-positive breast cancer, with ER inhibitors serving as first-line antiestrogens for the refractory phenotype of advanced cancer, acting by modulating ER transcriptional function [59, 60]. Here, ESR1 is linked to breast carcinoma.